Business
Bayer : Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
Bayer : Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop
About this update from Bayer Ag
Back to Newsroom Important notice This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus. This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange ( https://www.luxse.com ). The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. Agree Disagree Back to Newsroom Please confirm your location here: Choose country Australia Japan Canada South Africa USA Other Go Disclaimer - Important The following materials are not directed at or to be accessed by persons located in the United States, Australia, Canada or Japan. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. The securities mentioned herein have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of the securities in the United States. In the United Kingdom the following materials are only directed at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the materials or any of their contents. In relation to each member state of the European Economic Area which has implemented the Directive 2003/71/EC, and any amendments thereto (the "Prospectus Directive")(each a "Relevant Member State"), an offer to the public of the securities has not been made and will not be made in such Relevant Member State, except that an offer to the public in such Relevant Member State of any securities may be made at any time under the following exemptions from the Prospectus Directive, if they have been implemented in the Relevant Member State: to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, or in any other circumstances falling within Article 3(2) of the Prospectus Directive; provided that no such offer shall result in a requirement to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. For the purposes of this provision, the expression an "offer to the public" in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression "Prospectus Directive" includes any relevant implementing measure in each Relevant Member State. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. I Agree I Do Not Agree Back to Newsroom Please confirm your location here: Choose country Australia Japan Canada South Africa USA Other Go Important Notice This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus. This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange ( https://www.luxse.com ). The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act" ), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. I Agree I Do Not Agree Back to Newsroom Important notice This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus. This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange ( https://www.luxse.com ). The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. The tender offer referenced herein is not being made, directly or indirectly, in or into the United States by use of the mails or by any means or instrumentality (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of any facility of a national securities exchange of the United States and the tender offer cannot be accepted by any such use, means, instrumentality or facility or from within the United States. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. Agree Disagree Back to Newsroom Please confirm your location here: Choose country Australia Japan Canada South Africa USA Other Go Important Notice This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. I Agree I Do Not Agree Back to Newsroom Please confirm your location here: Choose country Australia Japan Canada South Africa USA Other Go Important Notice This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities. There will be no public offer of the securities in any jurisdiction. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. An investment decision regarding the securities referred to herein should only be made on the basis of the securities prospectus. This announcement is an advertisement and does not, under any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129. The final prospectus, when published, will be available on the website of the Luxembourg Stock Exchange ( https://www.luxse.com ). The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act" ), or any U.S. State security laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Basis of access Access to electronic versions of these materials is being made available on this webpage by Bayer in good faith and for information purposes only. Making press announcements and other documents available in electronic format on this webpage does not constitute an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Further, it does not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Confirmation of understanding and acceptance of disclaimer By clicking on the "I AGREE" button, I certify that I am not located in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is prohibited or restricted. I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the "I AGREE" button, I confirm that I am permitted to proceed to electronic versions of these materials. I Agree I Do Not Agree Back to Newsroom Disclaimer This website is intended to provide information to an international audience outside the USA and UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal. I hereby confirm that I am a medical journalist outside the UK and the US. Continue Back to Newsroom Disclaimer This website is intended to provide information to an international audience outside the UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer press portal. I hereby confirm that I am a medical journalist outside the UK. Continue Export-LatestNews Company Business & Finance Research & Innovation Bayer July 14 , 2026 | 13:00 PM Europe/Amsterdam Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming Summary Funding supports commercialization and sales growth expansion, targeting hundreds of new farms in the next 12 months / Autonomy technology is designed to lower capital expenditures and unlock the ability to scale operations more efficiently / Sabanto's physical AI makes swarm operations possible so that growers can replace horsepower with time Ames, IA, July 14, 2026 -Sabanto, a leader in autonomous retrofit technology for agriculture, today announced an oversubscribed Series B funding led by Leaps by Bayer with participation by Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The round will accelerate broad adoption of autonomous technology, expand customer base, and further develop autonomy retrofit kits across North America and beyond. Sabanto's ambition for scale comes at a critical time for agriculture, as growers face historic tighter margins via rising equipment and input costs, labor shortages, and increasing pressure to maximize productivity. While well-known equipment manufacturers or OEMs are focusing on bigger and more expensive machines, Sabanto's retrofit autonomy platform offers farmers a lower-capital pathway to profitability by utilizing existing, less-expensive, and smaller horsepower equipment. By enabling tractors to operate autonomously during planting and other field operations, Sabanto helps growers extend operating hours to virtually any time of day while reducing dependency on seasonal labor constraints. Autonomous retrofit technology will increasingly allow farm operators to reallocate skilled labor toward logistics, agronomic decision-making, and operational expansion. "This investment represents a major step forward in bringing practical autonomy to more farms," said Craig Rupp, CEO and founder of Sabanto. "We believe the workhorse of the future is smaller equipment. Our retrofit approach allows farmers to shift labor toward higher-value tasks, increase operating hours, and ultimately focus on growing their business and their bottom line. We're seeing too many farms fold under economic pressure and our solution levels the playing field." The investment will support: ● Expanded commercialization and dealer network growth ● Increased retrofit kit production and deployment ● Continued software and autonomy platform development ● Expanded customer support and field operations ● Accelerated adoption within the row crop market Sabanto recently expanded autonomous functionality into planting operations, allowing growers to maximize critical planting windows by operating equipment around the clock. New integrations with Precision Planting ® and DICKEY-john ® monitoring systems further enhance compatibility with widely used precision agriculture technologies, enabling seamless operation for growers already invested in modern planting systems. Sabanto's funding round also aligns closely with Bayer's long-term sustainability and environmental objectives of better use of land and resources, more regenerative practices, and win-win solutions for the diverse needs of people and our planet. Sabanto's retrofit model enables growers to utilize smaller, lighter equipment platforms that can help reduce soil compaction compared to larger traditional machinery, supporting improved soil health and long-term field productivity. Autonomous operations can also optimize machine efficiency by reducing inefficiencies such as overlaps, minimizing idle time, and improving route consistency, contributing to lower fuel consumption during field operations. Sabanto's autonomy platform is designed to work in concert with increasingly "smart" implements and precision agriculture systems, helping growers better manage fertilizer applications, seed placement, spraying, and other critical inputs. By combining autonomy with precision technologies, growers can reduce input waste, improve operational accuracy, and lower overall cost per acre, while still being mindful of the environment. "Farmers today need solutions that improve efficiency without requiring massive capital expenditures," said Paimun Amini, VP of Agriculture Venture Investments at Leaps by Bayer. "Sabanto's retrofit model offers a scalable and practical pathway to autonomy, especially in today's challenging farm economy. We believe this technology offers options that can reshape how labor and equipment are utilized in row crop farming and beyond while also supporting more sustainable farming practices." Photos and videos are available in this folder . About Sabanto Sabanto is a midwest-based agricultural technology firm focused on delivering physical AI-enabled, retrofit autonomous solutions for farming operations across multiple industry segments. Sabanto's Retrofit Autonomy Kit transforms off-the-shelf tractors into fully autonomous machines. The kit includes a cloud-connected communications system, multiple GNSS receivers, and an onboard AI processing unit, and can be installed in a single day. By upfitting existing equipment to operate autonomously, Sabanto helps growers reduce time & labor constraints, maximize machine output, and ultimately improve operational efficiency across a range of agricultural applications. About Leaps by Bayer Leaps by Bayer aims to solve ten huge challenges or 'Leaps' through scientific breakthroughs. As the strategic investment unit of Bayer, Leaps has invested over $2.1 billion in more than 65 companies innovating emerging platforms and technologies in health and agriculture. www.leaps.bayer.com Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to "Bayer" or "the company" herein may refer to one or more subsidiaries as context requires. Contact Kira Peikoff Deputy Director Communications [email protected] +1 973 791 3348 Downloads 2026-0117e.pdf 2026-0117e.rtf Newsroom Sign up for our Newsletter We will keep you informed about the latest news. Sign up